Floatz logo

Tulmimetostat

Lymphoma, T-Cell

Novartis PharmaceuticalsSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

84 Active assets in the Lymphoma, T-Cell cohort.

Asset / SponsorPhaseRating
Fludarabine
GC Cell Corporation
Phase 2BBB
Brentuximab Vedotin
Yale University
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Memorial Sloan Kettering Cancer Center
Phase 2BB
cc-5013
Samsung Medical Center
Phase 2BB
Cyclophosphamide
GC Cell Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

Tulmimetostat is also rated in:

metastatic prostate carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
Ovarian Clear Cell CarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
malignant mesotheliomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →